Investigating how specific proteins in brain cells contribute to Alzheimer's disease.
Official title: Neuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer's disease.
Funded at Yale University · NIH-10868445 · Data updated 2026-11-12
This study is looking at how certain brain cells change as we age and in Alzheimer's disease, to find out how these changes might help us discover new ways to treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | December 15, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $948,518 |
| NIH project number | 5R01AG075820-05 |
| Project ID | NIH-10868445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing cognitive decline or diagnosed with Alzheimer's disease.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on understanding the roles of neurons and microglia in Alzheimer's disease (AD) by examining the proteins involved in their functioning. The study utilizes a novel technique to analyze protein changes in these brain cells as they age and in the context of AD. By inhibiting a specific signaling pathway known as MAPK/ERK, researchers aim to uncover how these changes affect brain cell behavior and identify potential biomarkers for the disease. This approach could lead to new therapeutic strategies for AD.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and treatments for Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in neurodegenerative diseases, suggesting potential for success in this approach.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Rangaraju, Srikant — Yale University
- Study coordinator: Rangaraju, Srikant
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.